The first drug profiled, etomidate, has been improved by researchers at Massachusetts General Hospital. The researchers were able to improve the drug so that it does not interfere with the immune system, a current side effect of the agent.
The second, remimazolam, is a new benzodiazepine-type sedative drug with predictable effects and a comparatively rapid recovery time.
More Articles on Anesthesia:
FDA Approves Mylan’s Generic Anesthesia Drug Etomidate
Improving Perioperative Efficiency, Quality Requires Nursing-Anesthesia Partnership
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
